Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Up 7.8% – Here’s What Happened

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)’s share price traded up 7.8% on Tuesday . The company traded as high as $19.57 and last traded at $20.1190. Approximately 341,754 shares changed hands during trading, a decline of 74% from the average session volume of 1,304,115 shares. The stock had previously closed at $18.67.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on GLUE shares. Wall Street Zen cut shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Wells Fargo & Company dropped their price objective on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research note on Wednesday, March 18th. JPMorgan Chase & Co. boosted their target price on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Weiss Ratings upgraded Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Finally, Guggenheim lowered their price target on Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating on the stock in a report on Wednesday, March 18th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $32.50.

Monte Rosa Therapeutics Stock Up 8.7%

The stock has a 50-day simple moving average of $18.66 and a two-hundred day simple moving average of $18.52. The firm has a market cap of $1.72 billion, a PE ratio of -13.72 and a beta of 1.60.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%.The firm had revenue of $4.21 million for the quarter, compared to the consensus estimate of $10.95 million. Research analysts expect that Monte Rosa Therapeutics, Inc. will post -1.23 earnings per share for the current year.

Insider Buying and Selling

In other Monte Rosa Therapeutics news, insider Sharon Townson sold 3,000 shares of the stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $19.00, for a total transaction of $57,000.00. Following the transaction, the insider directly owned 67,845 shares in the company, valued at $1,289,055. This trade represents a 4.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Philip Nickson sold 5,845 shares of Monte Rosa Therapeutics stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $17.69, for a total transaction of $103,398.05. Following the transaction, the insider directly owned 55,000 shares in the company, valued at $972,950. This trade represents a 9.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 13,196 shares of company stock worth $245,242 in the last quarter. 6.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Monte Rosa Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC bought a new stake in Monte Rosa Therapeutics in the fourth quarter worth $30,000. Nisa Investment Advisors LLC grew its stake in shares of Monte Rosa Therapeutics by 16.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock valued at $49,000 after buying an additional 451 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Monte Rosa Therapeutics by 32.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock valued at $50,000 after buying an additional 776 shares during the last quarter. Seven Fleet Capital Management LP purchased a new position in shares of Monte Rosa Therapeutics in the fourth quarter worth about $63,000. Finally, Russell Investments Group Ltd. purchased a new position in shares of Monte Rosa Therapeutics in the third quarter worth about $32,000. Institutional investors own 79.96% of the company’s stock.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.